NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently put its aggressive growth strategy into effect with the additions of a new corporate controller, a head of its legal division and more office staff. The company also intends to increase its lab personnel in 2019. A recent article further discussing the company reads, “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, has announced aggressive growth plans, including the addition of key personnel, a special focus on its lab R&D activities in 2019 and the issue of new stock options. … It has added a new corporate controller, a head of its legal division and additional office staff. In addition, LXRP anticipates adding more lab personnel next year as it intensifies its R&D activities.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer